English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine Healthcare & Pharm
Sihuan Pharmaceutical Was Selected As One Of The First Echelon Of Enterprises In The list of China's Top 100 Pharmaceutical Innovative Enterprises in 2023
Oct 13, 2023 18:07 HKT
Cornerstone Robotics Shines Bright at ELSA2023, Latest Robotics Technology Captivates Attention
Oct 13, 2023 15:17 HKT
浙大邵逸夫醫院梁霄教授獲邀參加2023年亞洲腹腔鏡與內鏡外科醫師會議
Oct 11, 2023 19:10 HKT
Dr. LIANG Xiao of SRRSH Invited as ELSA 2023 Sole Keynote Speaker from Mainland China
Oct 11, 2023 19:09 HKT
New Frontier Group Achieves ISO 9001 Certification
Oct 10, 2023 21:00 HKT
A closer examination at JinMed's top-line growth trajectory, revealing an abundance growth potential
Oct 10, 2023 20:12 HKT
ONERHT Foundation Charity Golf 2023 raises more than S$400,000 for disadvantaged groups
Oct 09, 2023 15:00 HKT
医思健康携手晶钻生医举办美特拉拉提线新品发布会
Oct 06, 2023 18:56 HKT
醫思健康攜手晶鑽生醫舉辦美特拉拉提線新品發佈會
Oct 06, 2023 18:55 HKT
ACROMETA's Life Science Incubator (LSI) Signs Agreement with Ho Bee Land subsidiary to operate Co-Working Laboratory
Oct 06, 2023 17:30 HKT
Medi Lifestyle Limited Elevates Wound Care Innovations at Global Conference
Oct 06, 2023 16:00 HKT
Could Vegan Pet Food Help Save the Planet?
Oct 06, 2023 08:00 HKT
ZeptoMetrix Awarded in Vitro Diagnostic Regulation (IVDR) Certification
Oct 03, 2023 21:00 HKT
HanchorBio Announces First Patient Dosed in the Phase 1 Multi-Regional Clinical Trial of HCB101
Oct 03, 2023 19:30 HKT
绿竹生物核心产品重组带状疱疹疫苗LZ901于中国启动III期临床试验
Sep 29, 2023 10:31 HKT
綠竹生物核心產品重組帶狀皰疹疫苗LZ901於中國啟動III期臨床試驗
Sep 29, 2023 10:30 HKT
綠竹生物(02480.HK):重組帶狀皰疹疫苗LZ901啟動三期臨床研究 帶狀皰疹疫苗市場競爭迎新曙光
Sep 29, 2023 10:23 HKT
绿竹生物(02480.HK):重组带状疱疹疫苗LZ901启动三期临床研究 带状疱疹疫苗市场竞争迎新曙光
Sep 29, 2023 10:22 HKT
Hyris Supports Researchers and Developers to Launch Testing Kits via New Onboarding Programs
Sep 27, 2023 17:00 HKT
致力于开发中国双抗疗法的生物技术公司武汉友芝友生物于香港联交所主板正式挂牌
Sep 25, 2023 12:47 HKT
<< Previous  Next >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: